Dyne Therapeutics (NASDAQ:DYN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a hold rating in a research report released on Saturday.

Several other research firms have also recently commented on DYN. Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their price objective on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Morgan Stanley increased their target price on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.47.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $20.78 on Friday. The firm has a fifty day moving average of $19.84 and a 200-day moving average of $14.58. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -5.68 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $26.22.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. As a group, equities analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC grew its position in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after buying an additional 1,900 shares during the last quarter. Chung Wu Investment Group LLC acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $30,000. Quarry LP acquired a new position in shares of Dyne Therapeutics in the 1st quarter worth $47,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Dyne Therapeutics by 11.1% during the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after purchasing an additional 955 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.